Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Harvard Business School
McKinsey
Moodys
Dow

Last Updated: December 2, 2021

DrugPatentWatch Database Preview

Claims for Patent: 9,952,300

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,952,300
Title:Dynamic contrast enhanced MRI method and agents for the assessment of the macromolecular transport within pathologic tissues
Abstract: The present invention generally relates to paramagnetic contrast agents and a Dynamic Contrast Enhanced-MRI method for the non-invasive estimation of the delivery of a macromolecular anticancer drug or pro-drug within pathological tissues and, especially, in solid tumors and for the optimization of anticancer therapies.
Inventor(s): Giavazzi; Raffaella (Milan, IT), Maiocchi; Alessandro (Monza, IT), Moschetta; Michele (Trani, IT), Valbusa; Giovanni (Verbania, IT)
Assignee: BRACCO IMAGING S.P.A. (Milan, IT)
Application Number:14/382,585
Patent Claims:1. A Dynamic Contrast Enhanced-Magnetic Resonance Imaging (DCE-MRI) method for classifying a tumor or cancerous mass of an oncologic patient prior to treatment with an anticancer therapy comprising: a) administering an effective amount of a paramagnetic contrast agent having a molecular weight of 800 to 5000 Da, displaying a non-covalent binding with Human Serum Albumin of at least 85%, and comprising (i) at least one paramagnetic complex unit and (ii) at least one lipophilic moiety to the oncologic patient; (b) acquiring DCE-MRI images during the passage of the paramagnetic contrast agent within the oncologic patient; (c) identifying at least one region of interest within the DCE-MRI images; (d) obtaining a signal intensity curve within the at least one region of interest, wherein the signal intensity curve contains a plurality of signal intensity values; (e) converting the signal intensity values into contrast agent concentration values; (f) drafting a concentration-time curve; (g) fitting the concentration curve by a pharmacokinetic model; (h) deriving at least one parameter related to the pharmacokinetics displayed by the paramagnetic contrast agent, wherein the at least one parameter is measured, on a pixel-by-pixel or voxel-by-voxel basis, in at least one region of interest within the tumor or cancerous mass and in at least one reference region in the DCE-MRI images; (i) calculating a threshold value for the at least one parameter by determining the mean (.mu.) and standard deviation (.sigma.) of the at least one parameter, on a pixel-by-pixel or voxel-by-voxel basis, in the at least one reference region; (j) estimating the delivery of the anticancer therapy within the tumor or cancerous mass of the oncologic patient based on the at least one parameter by calculating a fraction D of pixels or voxels in the at least one region of interest having a value of the at least one parameter that exceeds the threshold value for the at least one parameter; and (k) classifying the tumor or cancerous mass of the oncologic patient as resistant or non-resistant to the anticancer therapy based on the fraction D, wherein the fraction D at least equal to 0.5 indicates that the tumor or cancerous mass of the patient is non-resistant to the anticancer therapy and the fraction D less than 0.5 indicates that the tumor or cancerous mass of the patient is resistant to the anticancer therapy, wherein the anticancer therapy is a macromolecular drug or pro-drug having a size comparable to or greater than that of albumin prior to intravenous injection or reaching the size upon intravenous injection, and wherein classification of the tumor or cancerous mass occurs prior to treatment with the anticancer therapy.

2. A DCE-MRI method according to claim 1 wherein the macromolecular drug or pro-drug is an antibody or an antibody fragment-based anticancer drug.

3. A DCE-MRI method according to claim 2 wherein the macromolecular drug or pro-drug is selected from the group consisting of Alemtuzumab, Bevacimmab, Brentuximab Vedotin, Cetuximab, Gemtuzumab, Ipilimumab, Panitumumab, Trastuzumab, Tositumomab and Rituximab.

4. A DCE-MRI method according to claim 1, wherein the at least one parameter is selected from the group consisting of: fractional plasma volume (f.sub.PV), volume transfer constant between blood plasma and extravascular extracellular space (K.sup.trans), average signal enhancement (ANVGENH), area under the concentration curve (AUC), area under the signal enhancement curve (AUCE), initial area under the time-concentration curve (IAUC.sub.T), initial area under the time-signal enhancement curve (IAUCE.sub.T), early AUC ratio (EARLYAUCRATIO), late AUC ratio (LATEAUCRATIO), and combinations thereof.

5. A DCE-MRI method according to claim 4 wherein the at least one parameter is selected from the group consisting of K.sup.trans and f.sub.PV.

6. A DCE-MRI method according to claim 1 wherein the paramagnetic contrast agent has a molecular weight of 800 to 3,000 Da and a terminal half-life value in human blood circulation of at least 4 hours.

7. A DCE-MRI method according to claim 1 wherein the paramagnetic contrast agent displays a non-covalent binding with the Human Serum Albumin higher than 90%.

8. A DCI-MRI method according to claim 1 wherein the paramagnetic contrast agent is a physiologically acceptable salt of a paramagnetic chelated complex selected from the group consisting of: Gadocoletic acid, a gadolinium complex of the MS 325, and a gadolinium complex of the AAZTA-deoxycholic acid.

Details for Patent 9,952,300

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 1997-11-26 ⤷  Free Forever Trial 2032-03-05
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Free Forever Trial 2032-03-05
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Free Forever Trial 2032-03-05
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 2001-05-07 ⤷  Free Forever Trial 2032-03-05
Genzyme Corporation LEMTRADA alemtuzumab Injection 103948 2014-11-14 ⤷  Free Forever Trial 2032-03-05
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 2004-10-12 ⤷  Free Forever Trial 2032-03-05
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
McKinsey
Dow
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.